Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OCUP

Ocuphire Pharma (OCUP) Stock Price, News & Analysis

Ocuphire Pharma logo

About Ocuphire Pharma Stock (NASDAQ:OCUP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.17
$1.46
52-Week Range
N/A
Volume
676,700 shs
Average Volume
171,840 shs
Market Capitalization
$30.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Receive OCUP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter.

OCUP Stock News Headlines

Shareholder group nominates slate of director candidates for Opus Genetics
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Opus Genetics reinstated with a Buy at H.C. Wainwright
Ocuphire Pharma, Inc. Announces Acquisition of Opus Genetics
See More Headlines

OCUP Stock Analysis - Frequently Asked Questions

Ocuphire Pharma, Inc. (NASDAQ:OCUP) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The business had revenue of $3.67 million for the quarter. Ocuphire Pharma had a negative trailing twelve-month return on equity of 30.19% and a negative net margin of 85.75%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/11/2023
Today
6/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCUP
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$18.00
Low Stock Price Target
$10.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.99 million
Pretax Margin
-85.68%

Debt

Sales & Book Value

Annual Sales
$16.45 million
Price / Cash Flow
N/A
Book Value
$2.20 per share
Price / Book
N/A

Miscellaneous

Free Float
24,469,000
Market Cap
$30.33 million
Optionable
Optionable
Beta
0.20
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:OCUP) was last updated on 6/27/2025 by MarketBeat.com Staff
From Our Partners